Related Experiment Videos
[Beta 2 microglobulin in serum--a "tumor marker" in malignant lymphomas?]
1Evangelisches Waldkrankenhaus Spandau, Berlin.
Medizinische Klinik (Munich, Germany : 1983)
|January 15, 1990
Summary
Serum beta 2-microglobulin levels correlate with lymphoma progression and regression. While elevated in 55% of patients, its clinical use as a tumor marker is limited by specificity and sensitivity.
Area of Science:
- Oncology
- Clinical Chemistry
Context:
- Malignant lymphomas, including Hodgkin and non-Hodgkin types, represent a significant group of hematological malignancies.
- Accurate staging and monitoring of disease progression are crucial for effective treatment strategies.
Purpose:
- To investigate the correlation between serum beta 2-microglobulin concentration and the staging and course of malignant lymphoma.
- To evaluate beta 2-microglobulin as a potential tumor-associated marker in lymphoma patients.
Summary:
- Serum beta 2-microglobulin was analyzed in 221 lymphoma patients, revealing elevated levels in 55% of cases.
- A strong correlation was observed between advanced tumor stages (III and IV) and higher beta 2-microglobulin concentrations.
- Longitudinal studies indicated that beta 2-microglobulin levels decreased with tumor regression during therapy and normalized in complete remission.
Impact:
- Beta 2-microglobulin demonstrates characteristics of a tumor-associated marker in malignant lymphomas.
- Despite its correlation with disease status, the marker's low specificity and sensitivity restrict its widespread clinical application for diagnosis or monitoring.